RESUMO
Inflammation plays a pivotal role in coronary heart disease. Dendritic cells (DCs) are principal players in inflammation and atherosclerosis. Although the percentage of circulating DC precursors in coronary heart disease have been investigated, circulating myeloid DC (mDC) and plasmacytoid DC (pDC) precursors have not been extensively studied, particularly in relation to the severity of coronary artery lesions in patients with coronary heart disease. In this study, we recruited controls (n = 29), patients with stable angina pectoris (SAP, n = 30), patients with unstable angina pectoris (UAP, n = 56), and patients with acute myocardial infarction (AMI, n = 50). The severity and extent of coronary artery lesions was evaluated by Gensini score, following coronary angiograms. The percentage of circulating mDC and pDC precursors was determined by fluorescence-activated cell sorting (FACS). Plasma levels of MCP-1 and MMP-9, which correlate with atherosclerosis and DC migration, were also measured. The percentage of circulating mDC precursors was reduced in patients with AMI and UAP compared with control and SAP patients, respectively (p < 0.01 for AMI vs. SAP and Control, p < 0.05 for UAP vs. SAP and Control). The percentage of circulating pDC precursors was not significant changed. The levels of plasma MMP-9 and MCP-1 and Genisi score were all increased in patients with AMI and UAP, compared to control and SAP patients, respectively (p < 0.01 for AMI vs. SAP and control, p < 0.05 for UAP vs. SAP and control). Overall, the percentage of circulating mDC precursors was negatively correlated with MCP-1 (p < 0.001), MMP-9 (p < 0.001) and Genisi scores (p < 0.001). Genisi scores were positively correlated with the levels of MCP-1 (p < 0.001) and MMP-9 (p < 0.001). Our study suggested that the percentage of circulating mDC precursors is negatively correlated with the severity and extent of coronary artery lesions in patients with coronary heart disease.
Assuntos
Doença da Artéria Coronariana/diagnóstico , Vasos Coronários/patologia , Células Dendríticas/imunologia , Placa Aterosclerótica , Adulto , Idoso , Idoso de 80 Anos ou mais , Angina Estável/diagnóstico , Angina Estável/imunologia , Angina Estável/patologia , Angina Instável/diagnóstico , Angina Instável/imunologia , Angina Instável/patologia , Biomarcadores/sangue , Estudos de Casos e Controles , Contagem de Células , Separação Celular/métodos , Quimiocina CCL2/sangue , Distribuição de Qui-Quadrado , Angiografia Coronária , Doença da Artéria Coronariana/sangue , Doença da Artéria Coronariana/imunologia , Doença da Artéria Coronariana/patologia , Vasos Coronários/diagnóstico por imagem , Progressão da Doença , Feminino , Citometria de Fluxo , Humanos , Masculino , Metaloproteinase 9 da Matriz/sangue , Pessoa de Meia-Idade , Infarto do Miocárdio/diagnóstico , Infarto do Miocárdio/imunologia , Infarto do Miocárdio/patologia , Valor Preditivo dos Testes , Índice de Gravidade de DoençaRESUMO
In the present study, the Caco-2 monolayer model and a four-site rat intestinal perfusion model were used to investigate the effects of vitamin E tocopherol polyethylene glycol succinate 1000 (TPGS) on the intestinal absorption of icariside II. Icariside II was analyzed by ultra-performance liquid chromatography (UPLC). After that its apparent permeability coefficients (Papp) and effective permeability (P*(eff)) were calculated. In the Caco-2 cell model, Papp values from the apical (AP) to the basolateral (BL) of icariside II were increased and its efflux ratios were markedly reduced in the presence of TPGS. However, either 0.25 mg/mL or 0.5 mg/mL of TPGS had no significant difference in promoting the absorption of icariside II. In four-site rat intestinal perfusion model, P*(eff) of icariside II were significantly increased by 0.5 mg/mL of TPGS in ileum and colon. The results suggest that TPGS could promote the intestinal absorption of icariside II.
Assuntos
Flavonoides/farmacocinética , Vitamina E/análogos & derivados , Algoritmos , Animais , Células CACO-2 , Cromatografia Líquida de Alta Pressão , Colo/efeitos dos fármacos , Colo/metabolismo , Impedância Elétrica , Humanos , Íleo/efeitos dos fármacos , Íleo/metabolismo , Técnicas In Vitro , Absorção Intestinal/efeitos dos fármacos , Masculino , Polietilenoglicóis/farmacologia , Ratos , Ratos Sprague-Dawley , Reprodutibilidade dos Testes , Vitamina E/farmacologiaRESUMO
BACKGROUND: Esophageal squamous cell carcinoma (ESCC) is one of the most common cancers in developing countries. The aim of the study was to determine the association between serum CD26 concentration and outcome of patients with ESCC. METHODS: A total of 183 patients with ESCC and 254 healthy controls were selected. Blood samples were obtained from the participants. The serum level of CD26 was detected using a commercial enzyme-linked immunosorbent assay kit. All patients were followed for 4 years unless they died of ESCC during the follow-up period. RESULTS: Compared with the controls, serum CD26 levels in the patients decreased at admission (p <0.001), recovered to normal 1 month after resection (p = 0.087), and declined again at the time of tumor relapse (p <0.001). During the follow-up period, 107 patients died of ESCC and 76 patients survived. Multivariate logistic regression analysis revealed that the low serum level of CD26 (<530 pg/mL) was associated with poor prognosis in the patients (OR: 5.42, 95% CI: 2.91-8.41). Survival analysis also suggested that the patients with high serum level of CD26 (≥530 pg/mL) had a survival advantage compared with the patients with low serum level of CD26 (<530 pg/mL) (p <0.001). CONCLUSIONS: Serum CD26 concentration might be an independent prognostic indicator in patients with ESCC. It might be also useful to detect recurrent tumor in postoperative patients.